.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Citi
Novartis
Cipla
Harvard Business School
US Department of Justice
UBS
McKinsey
Colorcon
Teva

Generated: December 15, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,699,885

« Back to Dashboard

Which drugs does patent 6,699,885 protect, and when does it expire?


Patent 6,699,885 protects ZEGERID OTC, ZEGERID, and MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE, and is included in four NDAs. There have been zero Paragraph IV challenges on Zegerid OTC and Zegerid

This patent has sixty-two patent family members in twenty-four countries.

Summary for Patent: 6,699,885

Title: Substituted benzimidazole dosage forms and methods of using same
Abstract:Disclosed herein are methods, kits, combinations, and compositions for treating gastric acid disorders employing pharmaceutical compositions comprising a proton pump inhibiting agent (PPI) and a buffering agent in a pharmaceutically acceptable carrier.
Inventor(s): Phillips; Jeffrey O. (Ashland, MO)
Assignee: The Curators of the University of Missouri (Columbia, MO)
Application Number:10/054,350
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form; Formulation;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Bayer Healthcare LlcZEGERID OTComeprazole; sodium bicarbonateCAPSULE;ORAL022281-001Dec 1, 2009OTCYesYes► Subscribe► Subscribe► SubscribeYY
Santarus IncZEGERIDomeprazole; sodium bicarbonateFOR SUSPENSION;ORAL021636-001Jun 15, 2004ABRXYesNo► Subscribe► Subscribe► SubscribeYSHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER; TREATMENT OF HEARTBURN AND OTHER SYMPTOMS ASSOCIATED WITH GERD; SHORT-TERM TREATMENT OF EROSIVE ESOPHAGITIS; MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS
Santarus IncZEGERIDomeprazole; sodium bicarbonateFOR SUSPENSION;ORAL021636-002Dec 21, 2004ABRXYesYes► Subscribe► Subscribe► SubscribeYSHORT TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
Santarus IncZEGERIDomeprazole; sodium bicarbonateFOR SUSPENSION;ORAL021636-002Dec 21, 2004ABRXYesYes► Subscribe► Subscribe► SubscribeYREDUCTION OF RISK OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS
SantarusZEGERIDmagnesium hydroxide; omeprazole; sodium bicarbonateTABLET, CHEWABLE;ORAL021850-001Mar 24, 2006DISCNNoNo► Subscribe► Subscribe► SubscribeSHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER; TREATMENT OF HEARTBURN AND OTHER SYMPTOMS ASSOCIATED WITH GERD; SHORT-TERM TREATMENT OF EROSIVE ESOPHAGITIS; MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS
SantarusZEGERIDmagnesium hydroxide; omeprazole; sodium bicarbonateTABLET, CHEWABLE;ORAL021850-002Mar 24, 2006DISCNNoNo► Subscribe► Subscribe► SubscribeSHORT TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
SantarusMAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATEmagnesium hydroxide; omeprazole; sodium bicarbonateTABLET;ORAL022456-001Dec 4, 2009DISCNNoNo► Subscribe► Subscribe► SubscribeYSHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER; TREATMENT OF HEARTBURN AND OTHER SYMPTOMS ASSOCIATED WITH GERD; SHORT-TERM TREATMENT OF EROSIVE ESOPHAGITIS; MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS
SantarusMAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATEmagnesium hydroxide; omeprazole; sodium bicarbonateTABLET;ORAL022456-001Dec 4, 2009DISCNNoNo► Subscribe► Subscribe► SubscribeYSHORT-TERM TREATMENT (4-8 WEEKS) OF ACTIVE BENIGN GASTRIC ULCER
SantarusMAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATEmagnesium hydroxide; omeprazole; sodium bicarbonateTABLET;ORAL022456-002Dec 4, 2009DISCNNoNo► Subscribe► Subscribe► SubscribeYSHORT-TERM TREATMENT (4-8 WEEKS) OF ACTIVE BENIGN GASTRIC ULCER
SantarusMAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATEmagnesium hydroxide; omeprazole; sodium bicarbonateTABLET;ORAL022456-002Dec 4, 2009DISCNNoNo► Subscribe► Subscribe► SubscribeYSHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER; TREATMENT OF HEARTBURN AND OTHER SYMPTOMS ASSOCIATED WITH GERD; SHORT-TERM TREATMENT OF EROSIVE ESOPHAGITIS; MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 6,699,885

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,840,737 Omeprazole solution and method for using same► Subscribe
RE45198Omeprazole solution and method for using same► Subscribe
6,780,882 Substituted benzimidazole dosage forms and method of using same► Subscribe
7,399,772Substituted benzimidazole dosage forms and method of using same► Subscribe
6,645,988 Substituted benzimidazole dosage forms and method of using same► Subscribe
6,489,346 Substituted benzimidazole dosage forms and method of using same► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,699,885

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Taiwan200303220► Subscribe
Russian Federation2279276► Subscribe
Russian Federation2002121623► Subscribe
Portugal1246622► Subscribe
Poland374832► Subscribe
Poland367272► Subscribe
Poland201906► Subscribe
Poland357144► Subscribe
New Zealand520121► Subscribe
Norway20043442► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Novartis
Boehringer Ingelheim
Moodys
Cipla
Deloitte
US Department of Justice
Medtronic
AstraZeneca
Argus Health
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot